Do you handle complete eCTD publishing?

Yes: module authoring, compilation, hyperlinking, validation, and dispatch in eCTD format, plus lifecycle sequence management for amendments and variations.

What is the difference between a CTA/IND and a marketing application?

A Clinical Trial Application (CTA) or IND seeks regulatory clearance to conduct a clinical trial. A marketing application (such as an NDA, ANDA, or MAA) seeks authorization to market the product after trials are complete. ExcelRegX supports both ends of that lifecycle.

Can you rescue a submission that received deficiencies?

Yes. We perform a root-cause assessment of the deficiency letter, build a clear response strategy, and manage the resubmission, including direct agency communication where appropriate.

Do you support labeling and prescribing information?

Yes. We develop and maintain prescribing information, package inserts, and patient information leaflets, and manage labeling updates to keep them aligned with approved dossiers and regulatory requirements.

When should we engage regulatory support in our program?

Ideally at pre-IND stage: early scientific advice and pathway planning help prevent costly protocol and CMC rework. That said, we regularly join programs mid-development and stabilize the regulatory position from there.

Division 04

Regulatory Affairs From Pre-IND to Approval

ExcelRegX·Regulatory Affairs

ExcelRegX guides your product from pre-IND engagement through marketing authorization and beyond, building compliant submissions positioned for efficient review by FDA, EMA, MHRA, and CDSCO.

Talk to us Explore capabilities

95% First-Cycle

Acceptance Performance

INDNDAANDA

Regulatory approval as a strategy, not a hurdle

Regulatory clearance is one of the highest-stakes milestones in bringing a therapy to market. Our regulatory professionals track the evolving expectations of global health authorities and build submissions positioned for efficient, first-cycle review rather than repeated deficiency-response loops.

We support the full product lifecycle: regulatory strategy planning, submission management, agency negotiation, and post-approval variation coordination that keeps your authorization compliant and commercially active.

Strategy Before Submission: Pathway planning and agency alignment before dossier work begins, so deficiencies are designed out early.
Global Authority Fluency: Working knowledge of FDA, EMA, MHRA, TGA, and CDSCO expectations, formats, and precedents.
First-Cycle Discipline: Submission quality standards aimed at clean, efficient review and minimal avoidable deficiency cycles.
Dossier Craft: eCTD modules authored and quality-reviewed to each authority's structural and content expectations.
Lifecycle Continuity: The team that builds your submission maintains it: variations, renewals, and compliance, unbroken.
Compliance by Construction: Submissions built to withstand review and inspection, not just to reach the filing deadline.

What ExcelRegX delivers

Regulatory capability across the full lifecycle, from strategic planning through submission, negotiation, and post-approval maintenance.

Regulatory pathway and gap analysis
Target product profile and designation strategy (orphan, expedited)
Pre-IND / pre-submission planning
Multi-region submission strategy

How an ExcelRegX engagement runs

A structured regulatory lifecycle that converts strategy into approvals.

01
Gap Assessment
Your data package assessed against target-market requirements, so gaps are identified before they become deficiencies.
02
Strategy & Pathway Planning
Optimal regulatory pathway, designations, and agency engagement plan defined.
03
Dossier Development
eCTD-compliant modules authored, compiled, and quality-reviewed to authority standards.
04
Submission & Negotiation
Submission management plus structured, rapid response to agency questions.
05
Post-Approval Lifecycle
Variations, renewals, and ongoing compliance managed to protect your authorization.

Why sponsors choose ExcelRegX

Deficiencies designed out, not answered later: Strategic gap analysis before submission targets deficiencies early, reducing avoidable review cycles.
India depth, global reach: CDSCO fluency combined with FDA, EMA, and MHRA submission experience, in one partner.
Structured, timely responses: Disciplined query-response management keeps agency interactions moving and review timelines on track.
Lifecycle continuity: The team that built your submission maintains it, with no knowledge loss at approval.
Strategy-led, not template-led: Every submission is shaped by a regulatory strategy for your specific product and markets.
One partner, many authorities: FDA, EMA, MHRA, and CDSCO expectations handled by a single coordinated regulatory team.

Who We Serve

The organizations ExcelRegX supports

Pharmaceutical Companies
Biotechnology Companies
Generic & Biosimilar Manufacturers
Medical Device Companies
CROs
Academic Research Organizations

Questions, answered

The essentials sponsors ask before engaging ExcelRegX. For anything more specific, our team is one conversation away.

We support submissions and interactions with US FDA, EMA, MHRA, TGA, and CDSCO, along with other regional authorities, including strategy for multi-region parallel submissions.